arrow
R

Richard F. Olsson

karolinska institutet
H指数:51
被引数:7,977

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

PRIMAVERA: A Modular Phase I/II Study to Evaluate the Safety, Tolerability, and Efficacy of AZD3470, a Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, in Participants with Relapsed/Refractory Hematologic Malignancies

PRIMAVERA:一项模块化I/II期研究,旨在评估AZD3470(一种蛋白质精氨酸甲基转移酶5 [PRMT5] 抑制剂)在复发/难治性血液恶性肿瘤受试者中的安全性、耐受性和有效性

BLOOD
IF23.1
2024-11-050
PRE
Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study
2023-03-0161
OA
Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML
2022-02-0111
OAAI
Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia

单倍体与同胞,无关或脐带血造血细胞移植治疗急性淋巴细胞白血病

2022-01-1148
OAAI
Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes

氟达拉滨和美法仑与减少剂量的白消安和氟达拉滨相比,可改善老年骨髓增生异常综合征患者的移植结局

2021-11-0118
OAAI
Allogeneic Transplantation to Treat Therapy-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Adults
2021-11-0121
OAAI
Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era (vol 34, pg 3338, 2020)
LEUKEMIA
IF13.4
2021-06-050
OAAI
Impact of Pretransplantation Renal Dysfunction on Outcomes after Allogeneic Hematopoietic Cell Transplantation

移植前肾功能不全对异基因造血干细胞移植预后的影响

2021-05-0115
OAAI
Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era (vol 34, pg 3338, 2020)
LEUKEMIA
IF13.4
2021-03-290
OAAI
Bortezomib-Based Induction Is Associated with Superior Outcomes in Light Chain Amyloidosis Patients Treated with Autologous Hematopoietic Cell Transplantation Regardless of Plasma Cell Burden
2021-03-0114
OAAI
Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myelogenous Leukemia and Myelodysplastic Syndromes with Low/Intermediate but not High Disease Risk Index: A Center for International Blood and Marrow Transplant Research Study
2021-01-0117
OAAI
Community health status and outcomes after allogeneic hematopoietic cell transplantation in the United States

美国异基因造血干细胞移植后的社区健康状况和结局

CANCER
IF5.1
2020-10-2113
OAAI
Comparison of outcomes of HCT in blast phase of BCR-ABL1- MPN with de novo AML and with AML following MDS
2020-10-0218
OAAI
Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma
CANCER
IF5.1
2020-09-2355
OAAI
Subsequent neoplasms and late mortality in children undergoing allogeneic transplantation for nonmalignant diseases
2020-05-1221
OAAI
Survival following allogeneic transplant in patients with myelofibrosis
2020-05-0870
OAAI
Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era
LEUKEMIA
IF13.4
2020-04-2031
OAAI